ABL1 and cancer: ABL1 was positively correlated with five TFs (Figure 4D), suggesting that the FDA-approved anti-cancer therapeutic drug imatinib could be repurposed for high-EMT tumors with energy metabolic reprogramming in poor prognostic outcomes.